Company intelligence / Profile preview

Crestone Partners

Boulder, Colorado, United Statescrestonepartners.net ↗

Ownership: Private
Employees: ~78
Development stage: Other

Overview

Crestone’s lead candidate CRS3123 has demonstrated positive results in a Phase 2 clinical trial for C. difficile infection, meeting its primary endpoint with high rates of clinical cure and very low recurrence rates. The compound is generally safe and well tolerated[3]. Additional programs are at preclinical or early clinical stages.

Therapeutic areas: ImmunologyPsychiatryRare DiseasesInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Cystic Fibrosis Foundation funding for NTM program[5]Research collaborations with Colorado State University and Johns Hopkins University[5]National Jewish Health collaboration on resistance mechanisms[5]

Beyond the preview

Go deeper on Crestone Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crestone Partners.

Explore the full profile